Lonivizumab (Lucentis) long-term course after intraocular injection for severe prematurity retinopathy

KAKEN

About This Project

Japan Grant Number
JP26461650 (JGN)
Funding Program
Grants-in-Aid for Scientific Research
Funding Organization
Japan Society for the Promotion of Science

Kakenhi Information

Project/Area Number
26461650
Research Category
Grant-in-Aid for Scientific Research (C)
Allocation Type
  • Multi-year Fund
Review Section / Research Field
  • Biological Sciences > Medicine, Dentistry, and Pharmacy > Clinical internal medicine > Embryonic/Neonatal medicine
Research Institution
  • Fukuoka University
Project Period (FY)
2014-04-01 〜 2017-03-31
Project Status
Completed
Budget Amount*help
4,680,000 Yen (Direct Cost: 3,600,000 Yen Indirect Cost: 1,080,000 Yen)

Research Abstract

Thirty six eyes of eighteen cases with retinopathy of prematurity( ROP ) were treated by intravitreal injection of ranibizumab( IVR ), and the result was compared with Thirty four eyes of seventeen cases treated by intravitreal injection of bevacizumab( IVR ). Between IVR group and IVB group, there was no statistically significant differences on post-conception weeks at birth, body weight at birth, gestational weeks at treatment, body weight at treatment and severity of ROP. On all of eyes treated, ROP regressed once, and reactivated. On IVR group, reactivation occurred earlier than IVB group( six vs. nine weeks: p<0.01). There was no significant differences on gestational weeks at additional treatment, incidence of additional treatment, final outcome. None of the eye of both group progressed to retinal detachment. No significant difference on incidence of systemic adverse event was observed. IVR is effective as IVB on the treatment of ROP.

Related Articles

See more

Related Data

See more

Related Books

See more

Related Dissertations

See more

Related Projects

See more

Related Products

See more

Keywords

Details 詳細情報について

Back to top